{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:06:01Z","timestamp":1784696761881,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in patients with diabetes mellitus and comorbid depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was registered in PROSPERO (CRD420261305439). Eight electronic databases were searched up to February 11, 2026 for randomized controlled trials comparing SSRIs plus usual care versus control. Outcomes included depressive symptoms (HDRS, BDI), anxiety (HARS), glycaemic control (HbA1c, FPG, PPG), and BMI. Meta-analyses were performed using random-effects models; subgroup analysis by follow-up duration and sensitivity analysis were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nine RCTs (770 participants) were included. Overall, SSRIs did not significantly improve HDRS (MD = 0.16, 95% CI -0.69 to 1.01,\n                      <jats:italic>P = 0.72<\/jats:italic>\n                      ) or BDI scores. However, subgroup analysis showed significant HDRS reduction when follow-up was \u2265 6 months (MD = -0.96, 95% CI -1.86 to -0.05,\n                      <jats:italic>P = 0.04<\/jats:italic>\n                      ). SSRIs were associated with increased HARS scores (MD = 2.37, 95% CI 0.73 to 4.02,\n                      <jats:italic>P = 0.005<\/jats:italic>\n                      ). No significant effects were observed for HbA1c, FPG, PPG, or BMI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Preliminary evidence suggests that SSRIs may offer modest antidepressant benefits when used for \u2265 6 months in diabetic patients with depression, but they may be associated with a small increase in anxiety scores and do not appear to improve glycaemic control or BMI. However, the overall certainty of evidence is low to moderate. Monitoring of early anxiety symptoms is recommended, and further high-quality RCTs are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>\n                      , identifier CRD420261305439.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1891729","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:45:07Z","timestamp":1784695507000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of selective serotonin reuptake inhibitors for diabetes mellitus with depression: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuqing","family":"Zhang","sequence":"first","affiliation":[{"name":"Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilin","family":"Liu","sequence":"additional","affiliation":[{"name":"Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andong","family":"Li","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Nan","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00217-7","article-title":"Global, regional, and national cascades of diabetes care 2000-23: A systematic review and modelling analysis using findings from the Global Burden of Disease Study","volume":"13","author":"Stafford","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","article-title":"Depression in diabetes mellitus: A comprehensive review","volume":"16","author":"Andreoulakis","year":"2012","journal-title":"Hippokratia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.16281\/j.cnki.jocml.2020.36.167","article-title":"Current status and research progress in the treatment of diabetes mellitus complicated with depression","volume":"7","author":"Meng","year":"2020","journal-title":"Electronic J Clin Med Literature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12888-022-04494-x","article-title":"Determinants of depression and anxiety among type 2 diabetes patients in governments' hospitals at Harari Regional State, Eastern Ethiopia: A multi-center cross-sectional study","volume":"23","author":"Nigussie","year":"2023","journal-title":"BMC Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56068","article-title":"Association of anxiety and depressive symptoms and treatment adherence among patients with type 2 diabetes mellitus in Jazan, Saudi Arabia: A cross-sectional study","volume":"16","author":"Ali","year":"2024","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15630","article-title":"Depression and type 2 diabetes: A causal relationship and mechanistic pathway","volume":"26","author":"Khawagi","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1142\/9789812565822_0018","article-title":"Research progress of depression complicated by type 2 diabetes","volume":"15","author":"Su","year":"2013","journal-title":"Chin J Med Guide"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119467","article-title":"The bidirectional influence between type 2 diabetes mellitus and the state of depression and anxiety","volume":"1","author":"Xu","year":"2025","journal-title":"J Affect Disord"},{"key":"B9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3969\/j.issn.2095-140X.2015.09.010","article-title":"Status of Chinese and Western medicine study on diabetes patients with depression and anxiety","volume":"27","author":"Liu","year":"2015","journal-title":"Med Pharm J Chin People's Liberation Army"},{"key":"B10","article-title":"Advantages, disadvantages, and precautions of oral hypoglycemic agents","volume":"1","author":"Zhang","year":"2025","journal-title":"Chin J Diabetes Educ"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-015-1189-y","article-title":"Depression treatment and health-related quality of life among adults with diabetes and depression","volume":"25","author":"O","year":"2016","journal-title":"Qual Life Research: Int J Qual Life Aspects Treatment Care Rehabil"},{"key":"B12","article-title":"Clinical analysis of 146 cases of type 2 diabetes mellitus complicated with depression treated by psychological and behavioral intervention combined with pharmacotherapy","volume":"42","author":"Wang","year":"2013","journal-title":"Shanxi Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1177\/0269881198012003021","article-title":"Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology","volume":"12","author":"Goodnick","year":"1998","journal-title":"J Psychopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.Jad.2025.120048","article-title":"Antidepressant in treating myocardial infarction complicated with depression via 5-Ht\/inflammation from heart to brain","volume":"391","author":"Zhang","year":"2025","journal-title":"J Affect Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.Biopsych.2026.03.579","article-title":"345. Ssris are the safest antidepressants in patients at risk of atrial fibrillation: A class-based systematic review and meta-analysis","volume":"99","author":"Hamoudi","year":"2026","journal-title":"Biol Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13262","article-title":"Dose-response relationship of selective serotonin reuptake inhibitors","volume":"142","author":"Dold","year":"2020","journal-title":"Acta Psychiatr Scand"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.5.618","article-title":"Fluoxetine for depression in diabetes: A randomized double-blind placebo-controlled trial","volume":"23","author":"Lustman","year":"2000","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1825","article-title":"Efficacy of sertraline in prevention of depression recurrence in older versus younger adults with diabetes","volume":"30","author":"Williams","year":"2007","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/ijcp.12112","article-title":"Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus","volume":"67","author":"Karaiskos","year":"2013","journal-title":"Int J Clin Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S85711","article-title":"Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: A double-blind, randomized, clinical trial","volume":"11","author":"Kang","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1599","article-title":"Cognitive behavioral therapy versus sertraline in patients with depression and poorly controlled diabetes: The Diabetes and Depression (Dad) Study: A randomized controlled multicenter trial","volume":"38","author":"Petrak","year":"2015","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.13040\/ijpsr.0975-8232.6(10).4304-09","article-title":"Comparative effect of agomelatine versus escitalopram on glycemic control and symptoms of depression in patients with type 2 diabetes mellitus and depression","volume":"6","author":"Kumar","year":"2015","journal-title":"Int J Pharm Sci Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S167608","article-title":"Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: A single-blind randomized controlled trial","volume":"14","author":"Che","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_67_19","article-title":"Effect of sertraline as an add-on therapy in T2dm patients with comorbid depression: An open label randomized controlled trial","volume":"23","author":"Kumar","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.05.009","article-title":"Treatment of depression in type 2 diabetic patients: Effects on depressive symptoms, quality of life and metabolic control","volume":"101","author":"Nicolau","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1599","article-title":"Cognitive behavioral therapy versus sertraline in patients with depression and poorly controlled diabetes: The Diabetes and Depression (DAD) Study: A randomized controlled multicenter trial","volume":"38","author":"Petrak","year":"2015","journal-title":"Diabetes Care."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-025-00528-x","article-title":"The effect of sertraline on networks of mood and anxiety symptoms: Secondary analysis of the Panda randomized controlled trial","volume":"3","author":"Piazza","year":"2025","journal-title":"Nat Ment Health"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.156","article-title":"The molecular pathophysiology of depression and the new therapeutics","volume":"3","author":"Tian","year":"2022","journal-title":"MedComm"},{"key":"B29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/15622975.2022.2086295","article-title":"World Federation of Societies of Biological Psychiatry (Wfsbp) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders","volume":"24","author":"Bandelow","year":"2023","journal-title":"World J Biol Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41398-022-02285-2","article-title":"The complex clinical response to selective serotonin reuptake inhibitors in depression: A network perspective","volume":"13","author":"Boschloo","year":"2023","journal-title":"Transl Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2016.10.008","article-title":"5-Ht2c receptors in the Bnst are necessary for the enhancement of fear learning by selective serotonin reuptake inhibitors","volume":"136","author":"Pelrine","year":"2016","journal-title":"Neurobiol Learn Mem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011173","article-title":"Glucocorticoid receptor signaling in diabetes","volume":"22","author":"Kokkinopoulou","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/life15091422","article-title":"Glp-1 receptor agonists in mood disorders: A psychiatric perspective","volume":"15","author":"Carmellini","year":"2025","journal-title":"Life (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2633","article-title":"Fear of hypoglycemia-an underestimated problem","volume":"12","author":"Przezak","year":"2022","journal-title":"Brain Behav"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.071068","article-title":"Selective serotonin reuptake inhibitors for unipolar depression: A systematic review of classic long-term randomized controlled trials","volume":"178","author":"Deshauer","year":"2008","journal-title":"CMAJ"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v67n1219","article-title":"Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: The Hordaland Health Study","volume":"67","author":"Raeder","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106218","article-title":"Insulin resistance: The role in comorbid type 2 diabetes mellitus and depression","volume":"175","author":"Yao","year":"2025","journal-title":"Neurosci Biobehav Rev"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1891729\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:45:21Z","timestamp":1784695521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1891729\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":37,"alternative-id":["10.3389\/fendo.2026.1891729"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1891729","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1891729"}}